RE:RE:RE:AMCo's #1 DrugYou didn't recall that. You just searched my posts. For the record I sold VRX at 43.40 for a small profit. I still think the company will rebound though, but I don't really like the CEO. My average on CXR is 34 CAD. So yes I'm down here, but only because I got blindsided by the Brexit vote to leave...... I guess that would make you lucky. I think your luck is about to run out.
Lattice wrote: Wallop, I recall that you said the bad news was baked in to VRX back in April - and the price just kept spiralling down the sewer $15 since then. Yeah... your down big time on both these names. This isn't like playing in oils, Wallop: drugs have expiry dates while they are sitting happiiy stuffed into a channel. Just admit as a VRX and CXR trader you have been had.
wallop13 wrote: So what is your short angle? Negative headline risk? Generic drug controls risk? That's priced in already.
Besides, neither of those will effect the current cash flow that will rapidly increase shareholder value by axing debt. If the government wants tighter control, then so be it. That will take a lot of time to implement and the end result will be slower EBITDA growth then what was seen in the past (god forbid we don't double EBITDA every year). I'd be happy with EBITDA remaining flat at this share price, but it will likely continue its upward march once the GBP finds its footing. Once the debt is paid off, with today's EBITDA, CXR would produce over 50% annual return on the current share price. If that isn't value, I don't know what is.
Lattice wrote: Does anyone know the current status of Concordia's #1 Drug in the AMCo portfolio?
It represents 7% of international revenues and since AMCo purchased it in 2013 it is reported by the FT as having a 1209% price increase?
I also wanted to do an informal poll on this board:
1. When a company strips the brand of an existing drug, and then subsequently renames it as a generic, is it misleading to refer to it as a new pipeline product launch? (You may want to refer to Concordia's November 2015 press release when they announced first pipeline product launch of Nefopam... and I believe Concordia spelled "Accupan" incorrectly in this press release - it should have been spelled "Acupan"). Yes/No
2. When a company repacks a drug or reformulates an existing one by adding one molecule, is it misleading to call it a new pipleine product launch, while giving the reason for lack of disclosure as "proprietary information"? Yes/No
Rascals.